Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 236

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 236
---
.8%
  
    Thomas Mollick 
     2,438,598(4) 
     15.7%

    Named executive officers and directors 

    Michael J. Newman, Ph.D. 
     1,752,164(5) 
     11.8%
  
    Jeffrey A. Meckler 
     1,035,636(6) 
     6.8%
  
    Roger Waltzman, M.D. 
     83,750(7) 
      * 
  
    Walt A. Linscott, Esq. 
     325,750(8) 
     2.2%
  
    Hila Karah 
     41,281(9) 
     * 
  
    Anthony J. Maddaluna 
     41,670(10) 
     * 
  
    William B. Hayes 
     41,000(11) 
     * 
  
    Dr. Roger J. Pomerantz 
     153,000(12) 
     1.1%
  
    Mark Gilbert, M.D. 
     46,250(13) 
     * 
  
    Robert E. Martell, M.D., Ph.D. 
     20,000(14) 
     * 
  
    All executive officers and directors as a group (11 persons) 
     3,690,334(15) 
     22.3%

    *
    Less than one
    percent.

91

    (1)
    Based
solely upon a Schedule 13G/A filed with the SEC on August 17, 2023. 1,076,482 shares are held by the Anderson Family Trust U/A/D January
7, 2017 in which Glen R. Anderson is a trustee of the Anderson Family Trust and shares voting and dispositive control with his spouse,
and 113,918 shares are held by Mr. Anderson over which he has sole voting and dispositive power. The business address of Mr. Anderson
is 101 South 200 East, Suite 700, Salt Lake City, UT 84111.

    (2)
    Consists
    of (i) 1,071,231 shares of common stock, and (ii) 1,071,231 shares of common stock issuable upon exercise of warrants which are subject
    to either a 4.99% or 9.